Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onfekafusp alfa + doxorubicin
- Development stage
- Phase 3
- Lead developer
- Philogen
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Onfekafusp alfa + doxorubicin** is a combination therapy under clinical development for the first-line treatment of advanced or metastatic soft tissue sarcoma. Onfekafusp alfa (also known as L19TNF or Fibromun) is a fully human antibody-cytokine fusion protein that targets the extra domain-B (EDB) of fibronectin in tumor vasculature, delivering tumor necrosis factor (TNF) directly to the tumor site. This results in apoptosis of tumor endothelial cells, vascular disruption, increased tumor permeability, and enhanced uptake of chemotherapeutic agents, with the intent of generating a synergistic anti-tumor effect. Doxorubicin is an established small molecule chemotherapy agent that intercalates DNA and inhibits topoisomerase II, thereby slowing or stopping cancer cell growth. The combination regimen aims to improve outcomes compared to doxorubicin alone and address the limited therapeutic options for patients ineligible for surgical resection.[1][2][3][4][5][7]
- Other names
- L19-TNFL-19-TNFL 19-TNFonfekafusp alfaL19TNFL-19TNFL 19TNFdoxorubicinadriamycin
02
Targets
DNATOP2A (DNA topoisomerase II)ED-B (Fibronectin extra domain B)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)
Beyond the preview
Go deeper on onfekafusp alfa + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onfekafusp alfa + doxorubicin.